Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunity & Ageing
Published in: Immunity & Ageing 1/2014

Open Access 01-12-2014 | Review

The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer’s Disease

Authors: Federico Licastro, Ilaria Carbone, Elena Raschi, Elisa Porcellini

Published in: Immunity & Ageing | Issue 1/2014

Login to get access

Abstract

Alzheimer’s disease (AD) is a complex disease resulting in neurodegeneration and cognitive impairment. Investigations on environmental factors implicated in AD are scarce and the etiology of the disease remains up to now obscure. The disease’s pathogenesis may be multi-factorial and different etiological factors may converge during aging and induce an activation of brain microglia and macrophages. This microglia priming will result in chronic neuro-inflammation under chronic antigen activation. Infective agents may prime and drive iper-activation of microglia and be partially responsible of the induction of brain inflammation and decline of cognitive performances. Age-associated immune dis-functions induced by chronic sub-clinical infections appear to substantially contribute to the appearance of neuro-inflammation in the elderly. Individual predisposition to less efficient immune responses is another relevant factor contributing to impaired regulation of inflammatory responses and accelerated cognitive decline.
Life-long virus infection may play a pivotal role in activating peripheral and central inflammatory responses and in turn contributing to increased cognitive impairment in preclinical and clinical AD.
Appendix
Available only for authorised users
Literature
1.
2.
Terry RD: Neuropathological changes in Alzheimer disease. Prog Brain Res. 1994, 101: 383-390. 10.1016/S0079-6123(08)61964-0.CrossRefPubMed
3.
Trojanowski JQ, Clark CM, Schmidt ML, Arnold SE, Lee VM: Strategies for improving the postmortem neuropathological diagnosis of Alzheimer’s disease. Neurobiol Aging. 1997, 18 (4 Suppl): S75-S79. 10.1016/S0197-4580(97)00075-4.CrossRefPubMed
4.
Elman JA, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, Crowley S, O’Neil JP, Jagust WJ: Neural compensation in older people with brain amyloid-β deposition. Nat Neurosci. 2014, 17 (10): 1316-1318. 10.1038/nn.3806.PubMedCentralCrossRefPubMed
5.
O’Brien RJ, Wong PC: Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 2011, 34: 185-204. 10.1146/annurev-neuro-061010-113613.PubMedCentralCrossRefPubMed
6.
Nalivaeva NN, Turner AJ: The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013, 587 (13): 2046-2054. 10.1016/j.febslet.2013.05.010.CrossRefPubMed
7.
Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD: The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010, 5 (3): e9505-10.1371/journal.pone.0009505.PubMedCentralCrossRefPubMed
8.
White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, Hartshorn KL: Alzheimer’s associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One. 2014, 9 (7): e101364-10.1371/journal.pone.0101364.PubMedCentralCrossRefPubMed
9.
Porcellini E, Carbone I, Ianni M, Licastro F: Alzheimer’s disease gene signature says: beware of brain viral infections. Immun Ageing. 2010, 7: 16-10.1186/1742-4933-7-16.PubMedCentralCrossRefPubMed
10.
Licastro F, Carbone I, Ianni M, Porcellini E: Gene signature in Alzheimer’s disease and environmental factors: the virus chronicle. J Alzheimers Dis. 2011, 27 (4): 809-817.PubMed
11.
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V: Genome-wide association study identities variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009, 41: 1094-1099. 10.1038/ng.439.CrossRefPubMed
12.
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C: Genome-wide association study identities variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009, 41: 1088-1093. 10.1038/ng.440.PubMedCentralCrossRefPubMed
13.
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D: Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011, 43: 429-435. 10.1038/ng.803.PubMedCentralCrossRefPubMed
14.
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boevem BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT: Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011, 43: 436-441. 10.1038/ng.801.PubMedCentralCrossRefPubMed
15.
Wozniak MA, Mee AP, Itzhaki RF: Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol. 2009, 217 (1): 131-138. 10.1002/path.2449.CrossRefPubMed
16.
Itzhaki RF, Wozniak MA: Herpes simplex virus type 1 in Alzheimer’s disease: the enemy within. J Alzheimers Dis. 2008, 13: 393-405.PubMed
17.
Carter CJ: Interactions between the products of the herpes simplex genome and Alzheimer’s disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem Int. 2008, 52: 920-934. 10.1016/j.neuint.2007.11.003.CrossRefPubMed
18.
Burgos JS, Ramirez C, Sastre I, Valdivieso F: Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol. 2006, 80: 5383-5387. 10.1128/JVI.00006-06.PubMedCentralCrossRefPubMed
19.
Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y: Reactivation of HSV-1in the brain of patients with familial Alzheimer’s disease. J Med Virol. 2004, 73: 605-611. 10.1002/jmv.20133.CrossRefPubMed
20.
Piacentini R, De Chiara G, Li Puma DD, Ripoli C, Marcocci ME, Garaci E, Palamara AT, Grassi C: HSV-1 and Alzheimer’s disease: more than a hypothesis. Front Pharmacol. 2014, 5: 97-10.3389/fphar.2014.00097.PubMedCentralCrossRefPubMed
21.
Lövheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F: Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement. 2014, S1552-5260 (14): 02421-02422.
22.
Mancuso R1, Baglio F, Cabinio M, Calabrese E, Hernis A, Nemni R, Clerici M: Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer’s disease. J Alzheimers Dis. 2014, 38 (4): 741-745.PubMed
23.
Tsutsui Y, Kosugi I, Kawasaki H, Arai Y, Han GP, Li L, Kaneta M: Roles of neural stem progenitor cells in cytomegalovirus infection of the brain in mouse models. Pathol Int. 2008, 58 (5): 257-267. 10.1111/j.1440-1827.2008.02221.x.CrossRefPubMed
24.
Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A: Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009, 19: 47-56. 10.1002/rmv.598.CrossRefPubMed
25.
Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE: Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011, 17 (6(2)): e16103-10.1371/journal.pone.0016103.CrossRef
26.
Koch S, Solana R, Dela Rosa O, Pawelec G: Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev. 2006, 127 (6): 538-543. 10.1016/j.mad.2006.01.011.CrossRefPubMed
27.
Rymkiewicz PD, Heng YX, Vasudev A, Larbi A: The immune system in the aging human. Immunol Res. 2012, 53 (1–3): 235-250. 10.1007/s12026-012-8289-3.CrossRefPubMed
28.
Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W: The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc. 2006, 54 (7): 1046-1054. 10.1111/j.1532-5415.2006.00796.x.CrossRefPubMed
29.
Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF: Herpesviruses in brain and Alzheimer’s disease. J Pathol. 2002, 197 (3): 395-402. 10.1002/path.1127.CrossRefPubMed
30.
Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ: Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging. 2004, 25 (5): 619-627. 10.1016/j.neurobiolaging.2003.12.021.CrossRefPubMed
31.
Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, Licastro F: Herpes virus in Alzheimer’s disease: relation to progression of the disease. Neurobiol Aging. 2014, 35 (1): 122-129. 10.1016/j.neurobiolaging.2013.06.024.CrossRefPubMed
32.
Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, Bennett DA: Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis. 2014, pii: jiu437-
33.
Kutok JL, Wang F: Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol. 2006, 1: 375-404. 10.1146/annurev.pathol.1.110304.100209.CrossRefPubMed
34.
Kleines M, Schiefer J, Stienen A, Blaum M, Ritter K, Häusler M: Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity. Eur J Clin Microbiol Infect Dis. 2011, 30 (12): 1561-1569. 10.1007/s10096-011-1261-7.CrossRefPubMed
35.
Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM: Epstein-barr virus in the multiple sclerosis brain: a controversial issue–report on a focused workshop held in the centre for brain research of the medical university of Vienna, Austria. Brain. 2011, 134 (Pt 9): 2772-2786. 10.1093/brain/awr197.PubMedCentralCrossRefPubMed
36.
Yao K, Crawford JR, Komaroff AL, Ablashi DV, Jacobson S: Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol. 2010, 82 (10): 1669-1678. 10.1002/jmv.21861.CrossRefPubMed
37.
Hemling N, Röyttä M, Rinne J, Pöllänen P, Broberg E, Tapio V, Vahlberg T, Hukkanen V: Herpesviruses in brains in Alzheimer’s and Parkinson’s diseases. Ann Neurol. 2003, 54 (2): 267-271. 10.1002/ana.10662.CrossRefPubMed
38.
Lang PO, Govind S, Aspinall R: Reversing T cell immunosenescence: why, who, and how. Age (Dordr). 2013, 35 (3): 609-620. 10.1007/s11357-012-9393-y.CrossRef
39.
40.
Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E, Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B: CMV and Immunosenescence: from basics to clinics. Immun Ageing. 2012, 9 (1): 23-10.1186/1742-4933-9-23.PubMedCentralCrossRefPubMed
41.
42.
Olsson J, Wikby A, Johansson B, Löfgren S, Nilsson BO, Ferguson FG: Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000, 121 (1–3): 187-201.PubMed
43.
Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B: An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005, 60 (5): 556-565. 10.1093/gerona/60.5.556.CrossRefPubMed
44.
Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, Thor Straten P, Wikby A: Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006, 176 (4): 2645-2653. 10.4049/jimmunol.176.4.2645.CrossRefPubMed
45.
Buchholz VR1, Neuenhahn M, Busch DH: CD8+ T cell differentiation in the aging immune system: until the last clone standing. Curr Opin Immunol. 2011, 23 (4): 549-554. 10.1016/j.coi.2011.05.002.CrossRefPubMed
46.
47.
Gordon S: Do macrophage innate immune receptors enhance atherogenesis?. Dev Cell. 2003, 5 (5): 666-668. 10.1016/S1534-5807(03)00329-0.CrossRefPubMed
48.
Lynch MA: The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology. 2014, 141 (3): 292-301. 10.1111/imm.12156.PubMedCentralCrossRefPubMed
49.
Jimenez S1, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J: Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer’s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci. 2008, 28 (45): 11650-11661. 10.1523/JNEUROSCI.3024-08.2008.CrossRefPubMed
50.
Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA: Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J Alzheimers Dis. 2012, 28 (1): 147-161.PubMed
51.
Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ: Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009, 72 (1): 56-62. 10.1212/01.wnl.0000338622.27876.0d.PubMedCentralCrossRefPubMed
52.
Schuitemaker A1, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, Knol DL, Windhorst AD, Luurtsema G, Barkhof F, Jonker C, Lammertsma AA, Scheltens P, van Berckel BN: Microglial activation in Alzheimer’s disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiol Aging. 2013, 34 (1): 128-136. 10.1016/j.neurobiolaging.2012.04.021.CrossRefPubMed
53.
Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J, Eriksdotter M, Sambamurti K, Fitzgerald JM, Serhan CN, Granholm AC, Schultzberg M: Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement. 2014, S1552-5260 (14): 00030-00032.
54.
Monson NL, Ireland SJ, Ligocki AJ, Chen D, Rounds WH, Li M, Huebinger RM, Munro Cullum C, Greenberg BM, Stowe AM, Zhang R: Elevated CNS inflammation in patients with preclinical Alzheimer’s disease. J Cereb Blood Flow Metab. 2014, 34 (1): 30-33. 10.1038/jcbfm.2013.183.PubMedCentralCrossRefPubMed
55.
56.
Licastro F, Morini MC, Davis LJ, Malpassi P, Cucinotta D, Parente R, Melotti C, Savorani G: Increased chemiluminescence response of neutrophils from the peripheral blood of patients with senile dementia of the Alzheimer’s type. J Neuroimmunol. 1994, 51 (1): 21-26. 10.1016/0165-5728(94)90124-4.CrossRefPubMed
57.
Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM: Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain?. J Neuroimmunol. 2000, 103 (1): 97-102. 10.1016/S0165-5728(99)00226-X.CrossRefPubMed
58.
Licastro F, Morini MC, Polazzi E, Davis LJ: Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer’s disease: an acute phase reactant without the peripheral acute phase response. J Neuroimmunol. 1995, 57 (1–2): 71-75. 10.1016/0165-5728(94)00163-I.CrossRefPubMed
59.
Metti AL, Yaffe K, Boudreau RM, Ganguli M, Lopez OL, Stone KL, Cauley JA: Change in inflammatory markers and cognitive status in the oldest-old women from the study of osteoporotic fractures. J Am Geriatr Soc. 2014, 62 (4): 662-666. 10.1111/jgs.12739.PubMedCentralCrossRefPubMed
60.
Brosseron F, Krauthausen M, Kummer M, Heneka MT: Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview. Mol Neurobiol. 2014, 50 (2): 534-544. 10.1007/s12035-014-8657-1.PubMedCentralCrossRefPubMed
61.
Hermida AP, McDonald WM, Steenland K, Levey A: The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?. Expert Rev Neurother. 2012, 12 (11): 1339-1350. 10.1586/ern.12.127.PubMedCentralCrossRefPubMed
62.
Zhao SJ, Guo CN, Wang MQ, Chen WJ, Zhao YB: Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: a Chinese clinical study. Cytokine. 2012, 57 (2): 221-225. 10.1016/j.cyto.2011.11.006.CrossRefPubMed
63.
Gironi M, Borgiani B, Farina E, Mariani E, Cursano C, Alberoni M, Nemni R, Comi G, Buscema M, Furlan R, Grossi E: A global immune deficit in Alzheimer’s disease and mild cognitive impairment disclosed by a novel data mining process.J Alzheimers Dis 2014, [Epub ahead of print].,
64.
Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, Schneider JA: Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis. 2013, 208 (4): 564-572. 10.1093/infdis/jit210.PubMedCentralCrossRefPubMed
65.
Shoemark DK, Allen SJ: The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer’s disease.J Alzheimers Dis 2014, [Epub ahead of print].,
66.
Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D: Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimers Dement. 2012, 8 (3): 196-203. 10.1016/j.jalz.2011.04.006.CrossRefPubMed
67.
Loos BG: Systemic markers of inflammation in periodontitis. J Periodontol. 2005, 76 (11 Suppl): 2106-2115. 10.1902/jop.2005.76.11-S.2106.CrossRefPubMed
68.
Chiba-Falek O, Linnertz C, Guyton J, Gardner SD, Roses AD, McCarthy JJ, Patel K: Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet. 2012, 131 (12): 1911-1920. 10.1007/s00439-012-1220-0.CrossRefPubMed
69.
Rivera MF, Lee JY, Aneja M, Goswami V, Liu L, Velsko IM, Chukkapalli SS, Bhattacharyya I, Chen H, Lucas AR, Kesavalu LN: Polymicrobial infection with major periodontal pathogens induced periodontal disease and aortic atherosclerosis in hyperlipidemic ApoE(null) mice. PLoS One. 2013, 8 (2): e57178-10.1371/journal.pone.0057178.PubMedCentralCrossRefPubMed
70.
Fu P, Wang AM, He LY, Song JM, Xue JC, Wang CQ: Elevated serum ApoE levels are associated with bacterial infections in pediatric patients. J Microbiol Immunol Infect. 2014, 47 (2): 122-129. 10.1016/j.jmii.2013.05.010.CrossRefPubMed
71.
Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012, 485 (7399): 512-516.PubMedCentralPubMed
Metadata
Title
The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer’s Disease
Authors
Federico Licastro
Ilaria Carbone
Elena Raschi
Elisa Porcellini
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2014
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-014-0022-8

Other articles of this Issue 1/2014

Immunity & Ageing 1/2014 Go to the issue

Research

Ageing combines CD4 T cell lymphopenia in secondary lymphoid organs and T cell accumulation in gut associated lymphoid tissue

Review

Possible role of ABO system in age-related diseases and longevity: a narrative review

Hypothesis

Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction

Research

Air pollution and subclinical airway inflammation in the SALIA cohort study

Research

Depressive symptoms post hip fracture in older adults are associated with phenotypic and functional alterations in T cells

Research

The association between hearing impairment and polymorphisms of genes encoding inflammatory mediators in Japanese aged population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits